Despite decades of preclinical research, no experimentally derived therapies for sepsis have been successfully adopted into routine clinical practice. Factors that contribute to this crisis of translation include poor representation by preclinical models of the complex human condition of sepsis, bias in preclinical studies, as well as limitations of single-laboratory methodology. To overcome some of these shortcomings, multicentre preclinical studies—defined as a research experiment conducted in two or more research laboratories with a common protocol and analysis—are expected to maximize transparency, improve reproducibility, and enhance generalizability. The ultimate objective is to increase the efficiency and efficacy of bench-to-bedside translation for preclinical sepsis research and improve outcomes for patients with life-threatening infection. To this end, we organized the first meeting of the National Preclinical Sepsis Platform (NPSP). This multicentre preclinical research collaboration of Canadian sepsis researchers and stakeholders was established to study the pathophysiology of sepsis and accelerate movement of promising therapeutics into early phase clinical trials. Integrated knowledge translation and shared decision-making were emphasized to ensure the goals of the platform align with clinical researchers and patient partners. 29 participants from 10 independent labs attended and discussed four main topics: (1) objectives of the platform; (2) animal models of sepsis; (3) multicentre methodology and (4) outcomes for evaluation. A PIRO model (predisposition, insult, response, organ dysfunction) for experimental design was proposed to strengthen linkages with interdisciplinary researchers and key stakeholders. This platform represents an important resource for maximizing translational impact of preclinical sepsis research.

中文翻译：

---

国家临床败血症平台：开发加速加拿大败血症研究创新的框架

尽管进行了数十年的临床前研究，但尚无成功将脓毒症的实验性疗法成功用于常规临床实践。导致这种翻译危机的因素包括：败血症的复杂人类状况的临床前模型代表性差，临床前研究存在偏见以及单一实验室方法的局限性。为了克服其中的一些不足，多中心临床前研究（定义为在两个或两个以上具有相同实验方案和分析的研究实验室中进行的研究实验）有望实现最大程度的透明性，提高可重复性并增强通用性。最终目标是提高临床前败血症研究从台到床的翻译的效率和功效，并改善威胁生命的感染患者的治疗效果。为此，我们组织了国家临床前败血症平台（NPSP）的第一次会议。建立了加拿大脓毒症研究人员和利益相关者的这种多中心临床前研究合作关系，以研究脓毒症的病理生理学，并加速有希望的疗法进入早期临床试验的进程。强调集成的知识翻译和共享的决策制定，以确保平台的目标与临床研究人员和患者合作伙伴保持一致。来自10个独立实验室的29名参与者参加并讨论了四个主要主题：（1）平台目标；（2）败血症动物模型；（3）多中心方法论和（4）评估结果。提出了用于实验设计的PIRO模型（易感性，侮辱性，反应性，器官功能障碍），以加强与跨学科研究人员和关键利益相关者的联系。该平台代表了最大化临床败血症研究转化影响的重要资源。